|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||17.72 - 17.99|
|52-week range||10.85 - 33.82|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||19.29|
Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.
In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.
Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.
AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.
In December 2017, the FDA accepted Teva Pharmaceutical Industries’ (TEVA) BLA (Biologics License Application) for fremanezumab for the preventive treatment of migraine. In February 2018, the European Medicines Agency accepted the MAA (Marketing Authorization Application) for fremanezumab for the treatment of adults with episodic and chronic migraine. In January 2018, the FDA approved Teva Pharmaceutical’s Trisenox and tretinoin combination therapy for the treatment of individuals with newly-diagnosed, low-risk APL (acute promyelocytic leukemia) with a presence of PML/RAR alpha gene expression.
In 4Q17, Teva Pharmaceutical Industries’ (TEVA) specialty medicines segment generated revenues of $1.8 billion compared to $2.2 billion in 4Q16. That was a 19% YoY (year-over-year) decline.
In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) generic medicines segment reported revenues of $12.3 billion compared to $12 billion in 2016, which was a 2% YoY (year-over-year) growth.
In 4Q17, Teva Pharmaceutical Industries (TEVA) reported revenues of $5.5 billion compared to $6.5 billion in 4Q16. That’s a 16% growth on a YoY (year-over-year) basis and a 3% growth on a quarter-over-quarter basis.
Teva Pharmaceutical Industries Ltd. won a court ruling tossing a $235 million verdict over its copy of GlaxoSmithKline Plc’s Coreg heart drug.
Recently, Teva Pharmaceutical (TEVA) has witnessed trouble in its business due to a number of company-specific and macroeconomic factors. The Copaxone sales decline due to generic competition, the pricing pressures in the market, and the impairments recently recorded by Teva are among the major factors triggering the company’s restructuring to recuperate the decline in its sales and earnings. For more information, read The Key Challenges Teva Pharmaceutical Is Facing.
NEW YORK, March 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
As of December 31, 2017, Teva Pharmaceutical (TEVA) has debt of $32.5 billion compared to $35.8 billion at the end of 2016. The company has a debt payment of ~$3.5 billion due in fiscal 2018. Teva plans to pay down its debt using its operating cash flows and the cash flows resulting from its divestment of certain noncore and nonprofitable assets as part of its restructuring plan.
Teva Pharmaceutical (TEVA) has a number of key specialty assets that are touted as key long-term growth drivers for the company. Fremanezumab, a drug used for the treatment of migraines in adults, is one such product in the company’s specialty asset portfolio. The drug was accepted for review by the FDA in December 2017 and by the EMA (European Medicines Agency) in February 2018.
Teva Pharmaceutical (TEVA) is focused on advancing its specialty assets portfolio, one of its key growth drivers. The company’s specialty products portfolio is made up of Copaxone, Austedo, Fremanezumab, and a number of other assets that are in clinical trials, one of which is Fasinumab.
In December 2017, Teva Pharmaceutical (TEVA) laid down its restructuring plan, which included R&D (research and development) optimization involving the consolidation of its R&D sites while maintaining a robust R&D portfolio. For more details, read What’s Teva Pharmaceutical’s Research and Development Strategy? Since Teva laid out its restructuring plans, it has cut down 25 of its specialty area projects, representing ~27% of its R&D programs.
Teva Pharmaceuticals (TEVA) reported a GAAP (generally accepted accounting principles) operating loss of $13 billion in fiscal 4Q17, which it reported on February 8, 2018. This difference was the result of significant impairment charges related to Teva’s US generics business in fiscal 4Q17. In fiscal 4Q17, Teva recorded a non-GAAP adjustment of $15.3 billion, ~$11 billion of which was due to the impairment of goodwill related to the company’s US generics business.
Investor Update: How Is Teva's Restructuring Plan Progressing? Teva Pharmaceutical (TEVA) announced a restructuring plan in mid-December 2017. The announcement came after the company made some key leadership changes to recuperate from the dismal performance it saw over the last few quarters following its acquisition of Allergan’s (AGN) generics business and the negative impact of increasing generics business competition and pricing pressures.